Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm, Open-label, Single-center Study to Evaluate the Safety and Tolerability of Intravenous GEN6050X Gene Therapy in Ambulatory Boys With Duchenne Muscular Dystrophy (DMD)

Next Previous
Trial Profile

A Single-arm, Open-label, Single-center Study to Evaluate the Safety and Tolerability of Intravenous GEN6050X Gene Therapy in Ambulatory Boys With Duchenne Muscular Dystrophy (DMD)

Status: Recruiting
Phase of Trial: Phase 0

Latest Information Update: 10 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GEN 6050 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; First in man
  • Acronyms GEN6050XIIT

Most Recent Events

  • 06 Mar 2025 According to a GenAssist Ltd media release, data from this study will be presented at 2025 Muscular Dystrophy Association (MDA) Conference,from March 16-19th, 2025 at Hilton Anatole, Dallas, TX.
  • 06 Mar 2025 Results of topline efficacy data and Safety Update of GEN6050X for the First two Participants Dosed, published in the GenAssist Ltd Media Release
  • 06 Mar 2025 According to a GenAssist Ltd media release,the company has received clearance from the U.S Food and Drug Administration(FDA) for its Investigational New Drug (IND) application for GEN6050X,for Duchenne Muscular Dystrophy (DMD).The study is being conducted at Peking Union Medical College Hospital. Until now, two patients have been dosed. The first 10-year-old patient has finished six-month follow-up.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top